Search
Connect Biopharma Holdings Ltd
CNTBAdd to Watchlist
2.555USD
+0.005+0.20%
Market hours （ET）Quotes delayed by 15 min
160.90MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Connect Biopharma Holdings Ltd is 8.75, ranking 63 out of 387 in the Biotechnology & Medical Research industry. The average price target is 7.50, with a high of 10.00 and a low of 6.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
7.250
Target Price
+184.31%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Connect Biopharma Holdings Ltd
CNTB
8
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Connect Biopharma Holdings Ltd's expected revenue for the next quarter?
Connect Biopharma Holdings Ltd's expected revenue is 96.42K.
What is Connect Biopharma Holdings Ltd's price target?
Analysts forecast that Connect Biopharma Holdings Ltd's price target is USD 7.50, with the highest forecast at USD 10.00 and the lowest forecast at USD 6.00.
How have Connect Biopharma Holdings LtdCNTB's recent earnings per share performed?
The market expectation was USD -0.27, while Connect Biopharma Holdings LtdCNTB's earnings per share (EPS) for the previous quarter was USD -0.34. EPS for the next quarter is expected at USD -0.04.
What is the analyst rating for Connect Biopharma Holdings Ltd?
Based on the ratings of Connect Biopharma Holdings Ltd's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.